LOBE Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EDT
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€16.23M
Enterprise Value€25.61
Total Cash (Recent Filing)€5.21M
Total Debt (Recent Filing)€338.40K
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding308,182,160
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recent FinancingThe financing provides working capital and reduces immediate funding pressure, giving Lobe additional capacity to sustain operations and advance its development programs over the next several months.
S-100 Clinical ProgressProgressing S-100 toward human trials creates a defined development milestone and could improve the program’s partnering or commercialization potential if clinical development produces supportive results.
Positive Equity PositionThe shift to positive equity represents meaningful balance-sheet stabilization compared with earlier periods, providing a stronger capital base for continued development even though overall financial flexibility remains limited.
Bears Say
No Current RevenueThe absence of current revenue indicates that Lobe lacks an established commercial engine and remains dependent on financing, partnerships, or successful product development to create future operating income.
Widening Operating LossesLarge and worsening operating losses show that development spending is not yet supported by revenue, increasing the capital required to reach commercialization and raising the risk of further shareholder dilution.
Persistent Cash BurnNegative and deteriorating cash generation limits self-funding capacity, making continued reliance on external capital more likely and potentially constraining the pace of clinical development and other strategic initiatives.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was €0.01 and its highest was €0.08 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is €16.23M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Dec 18, 2026 which is in 111 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Jul 30, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 308,182,160 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -26%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in DE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―